❐ Definium Therapeutics at Jefferies Global Healthcare Conference in New York June 2026 ❐

Definium Therapeutics discusses the progression of their clinical development program, focusing on the therapeutic potential of their proprietary drug candidate, DFTX-120. The panel detail the recent phase 2 clinical trial results for DFTX-120 in patients with generalized anxiety disorder (GAD) and major depressive disorder (MDD), emphasizing the observed sustained efficacy post-single administration. The conversation covers the company’s plans for upcoming pivotal trial readouts scheduled for later in 2026 and articulates the strategy for clinical endpoints, participant monitoring, and potential label expansion. The speakers also underscore the long-term goal of improving accessibility to their psychedelic therapy through rigorous clinical validation and careful protocol design.